The downgrade from Buy to Neutral by Citigroup indicates a less optimistic outlook for Cano Health's stock. The significant reduction in the price target from $4 to $0.8 suggests that the analyst expects a substantial decrease in the stock's value. This could negatively impact investor sentiment and potentially lead to a decrease in the stock's price in the short term.